JCM
SYRS

Jacobi Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jacobi Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-120
Closed -$5K – 1379
2021
Q3 		$5K Hold
120
– – ﹤0.01% 1211
2021
Q2 		$7K Hold
120
– – ﹤0.01% 1109
2021
Q1 		$9K Buy
120
+20
+20% +$2.08K ﹤0.01% 1014
2020
Q4 		$11K Hold
100
– – ﹤0.01% 855
2020
Q3 		$9K Buy
+100
New +$11.4K ﹤0.01% 835

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jacobi Capital Management's SYRS Position: Q4 2021 in Review

Jacobi Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 120 shares — an estimated $5K sold.

Jacobi Capital Management first reported a position in SYRS in Q3 2020 and held it in 5 quarters. The position peaked at $11K in Q4 2020. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

  • Jacobi Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 120 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $5K.
  • Jacobi Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Jacobi Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.